U.S. markets closed

Mesoblast Limited (MESO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.22+0.23 (+3.29%)
At close: 4:00PM EDT

7.00 -0.22 (-3.05%)
After hours: 7:37PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close6.99
Open7.08
Bid6.93 x 800
Ask7.30 x 1200
Day's Range7.07 - 7.28
52 Week Range6.67 - 21.28
Volume112,716
Avg. Volume254,470
Market Cap871.014M
Beta (5Y Monthly)2.60
PE Ratio (TTM)N/A
EPS (TTM)-0.87
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.42
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?
    Zacks

    Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?

    Mesoblast Limited (MESO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • Why Mesoblast Limited Stock Is Jumping Today
    Motley Fool

    Why Mesoblast Limited Stock Is Jumping Today

    Shares of Mesoblast Limited (NASDAQ: MESO) are rising sharply on Friday after the company reported positive results from a clinical trial for one of its pipeline candidates, remestemcel-L. The biotech's stock was up 7.3% as of 3:22 p.m. EDT, after soaring by as much as 24.5% earlier in today's trading session. In a clinical trial investigating the efficacy of remestemcel-L in ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS), the medicine was shown to reduce mortality by 46% in patients under the age of 65 through day 60, but not in those aged 65 and older. Mesoblast CEO Silviu Itescu said, "Reduction in mortality in mechanically ventilated patients under 65 years old remains a critical unmet need since as many as 72% of currently hospitalized patients across the US with COVID-19 are in this age category."

  • Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory Distress
    Benzinga

    Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory Distress

    Mesoblast Limited (NASDAQ: MESO) has announced 60-day results from the randomized controlled trial of remestemcel-L in COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS), which had been halted after the third interim analysis, as previously announced. The trial enrolled 222 mechanically ventilated COVID-19 patients. Remestemcel-L reduced mortality by 46% through day 60 in the pre-specified population of 123 treated patients under age 65, 26% vs. 42%, Hazard Ratio (HR) 0.54. The treatment has similar effects on mortality in these patients with either moderate ARDS (HR 0.56) or severe ARDS (HR 0.56). The standard of care changed during the course of the trial to incorporate dexamethasone. Remestemcel-L reduced mortality through day 60 by 75% compared to controls in patients under 65 who received dexamethasone as part of their standard of care, 14% vs. 45%, HR 0.25. Remestemcel-L increased days alive off the ventilator within 60 days and reduced time to discharge from initial hospitalization compared to controls in patients under 65 who received dexamethasone. Mesoblast entered into a license and collaboration agreement with Novartis AG (NYSE: NVS) for the development, manufacture, and commercialization of remestemcel-L, with an initial focus on treating ARDS, including that associated with COVID-19. The company will hold a webcast at 9 A.M ET today. Price Action: MESO shares are up 5.1% at $7.59 in the premarket on the last check Friday. See more from BenzingaClick here for options trades from BenzingaAbbVie Beats Q1 Earnings On Strong Humira Sales, Raises Full-Year Profit ForecastHill-Rom Q2 Earnings Exceed Expectations; Raises Fiscal 2021 Outlook© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.